Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.65 |
| ▸ | PGR | P06401 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL6 | P05231 | 1/20 | 0.65 |
| ▸ | GLUL | P15104 | 1/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264554 | 0.99 | HIF1A (0.64) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL27748218 | 0.97 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL7095395 | 0.97 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL704875 | 0.96 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL11068491 | 0.96 | HIF1A (0.62) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL27781029 | 0.96 | HIF1A (0.66) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL122048 | 0.95 | HIF1A (0.63) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL677626 | 0.95 | HIF1A (0.61) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL22042713 | 0.94 | HIF1A (0.59) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL35449 | 0.94 | HIF1A (0.64) | HIF1AHSD17B10NR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598506-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | Eupraxia Pharmaceuticals Inc. (CA) | 2025-08-13 | — | — | EP | claimed |
| CN-119968199-A | Use of long-acting fluticasone propionate injection suspension for treating and preventing gastrointestinal tract inflammation | 优普顺药物公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2024077017-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | EUPRAXIA PHARMACEUTICALS INC. (CA) | 2024-04-11 | — | — | WO | claimed |
| CN-116396347-A | Preparation method of high-standard prednisolone succinate | 河南利华制药有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS (US) | 2022-03-10 | — | — | US | claimed |
| EP-3038660-B1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORP (US) | 2020-12-23 | — | — | EP | claimed |
| US-20180256599-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2018-09-13 | — | — | US | claimed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | claimed |
| CN-100546656-C | A kind of kidney-targeted medicine vector reaches prodrug, method for making and the application with its formation | UNIV SICHUAN (CN) | 2009-10-07 | — | — | CN | claimed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | claimed |
| US-20070077286-A1 | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | LTT BIO-PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | claimed |
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | claimed |
| CN-1879889-A | Kidney-targeted medicine vector and the formed prodrug, preparation method and uses | UNIV SICHUAN (CN) | 2006-12-20 | — | — | CN | claimed |
| CN-1861193-A | Kidney target precursor medicine, said prepn., its preparing method and application | UNIV SICHUAN (CN) | 2006-11-15 | — | — | CN | claimed |
| EP-1698329-A1 | DRUG-CONTAINING NANOPARTICLE, PROCESS FOR PRODUCING THE SAME AND PARENTERALLY ADMINISTERED PREPARATION FROM THE NANOPARTICLE | LTT Bio-Pharma Co., Ltd. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | claimed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| CN-120831439-A | Content detection method of prednisolone sodium succinate for injection | 南京恩泰医药科技有限公司 | 2025-10-24 | — | — | CN | disclosed |
| EP-4598506-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | Eupraxia Pharmaceuticals Inc. (CA) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025105899-A1 | GLYCOL CHITOSAN DERIVATIVE CAPABLE OF DOUBLE CROSSLINKING | 충남대학교산학협력단 | 2025-05-22 | — | — | WO | disclosed |
| CN-119968199-A | Use of long-acting fluticasone propionate injection suspension for treating and preventing gastrointestinal tract inflammation | 优普顺药物公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119707932-A | Ethanesulfonic acid salts of quinoline derivatives | 小野药品工业株式会社 | 2025-03-28 | — | — | CN | disclosed |
| EP-4527886-A1 | CELL-ADHESIVE COMPOSITION AND POLYMER-COATED MICROPARTICLES | Maruzen Petrochemical Co., Ltd. (JP) | 2025-03-26 | — | — | EP | disclosed |
| US-20250064749-A1 | CELL-ADHESIVE COMPOSITION AND POLYMER-COATED MICROPARTICLES | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2025-02-27 | — | — | US | disclosed |
| US-20250041170-A1 | OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-20240423907-A1 | Improved Nasal Administration of Pharmaceutical Formulations | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-119113101-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119012999-A | Improved nasal administration of pharmaceutical formulations | 思瑞诺医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4460284-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | Cyrano Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240336697-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118355029-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4380978-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024106024-A1 | TEMPERATURE-RESPONSIVE IONIC LIQUID, TRANSDERMAL ABSORPTION ENHANCING AGENT OR TRANSDERMAL ABSORPTION-ENHANCING AID INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID, AND PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID | 東レ株式会社 | 2024-05-23 | — | — | WO | disclosed |
| CN-118027126-A | Refining method of prednisolone | 江苏远大仙乐药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024077017-A1 | USE OF LONG-ACTING FLUTICASONE PROPIONATE INJECTABLE SUSPENSIONS FOR TREATING AND PREVENTING INFLAMMATIONS OF THE GASTROINTESTINAL TRACT | EUPRAXIA PHARMACEUTICALS INC. (CA) | 2024-04-11 | — | — | WO | disclosed |
| US-20240058452-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID | TORAY INDUSTRIES, INC. (JP) | 2024-02-22 | — | — | US | disclosed |
| WO-2023224111-A1 | CELL-ADHESIVE COMPOSITION AND POLYMER-COATED MICROPARTICLES | 丸善石油化学株式会社 | 2023-11-23 | — | — | WO | disclosed |
| CN-111670203-B | bispecific antibodies | 小野药品工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| EP-3322482-B1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | TAP PHARMACEUTICALS AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023133460-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | CYRANO THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116396347-A | Preparation method of high-standard prednisolone succinate | 河南利华制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396347-A | Preparation method of high-standard prednisolone succinate | 河南利华制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396347-A | Preparation method of high-standard prednisolone succinate | 河南利华制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023090454-A1 | OILY SOLID COMPOSITION FOR EXTERNAL USE | ザ メンソレータム カンパニー | 2023-05-25 | — | — | WO | disclosed |
| CN-114502142-B | Pharmaceutical composition comprising temperature responsive ionic liquid | 东丽株式会社 | 2023-05-09 | — | — | CN | disclosed |
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023019092-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230041980-A1 | METHOD OF PROTECTING A RESPIRATORY TRACT OR A LUNG FROM DAMAGE, METHOD OF PROTECTING A LUNG FROM PRESSURE DAMAGE INDUCED BY A VENTILATOR, METHOD OF SUPPRESSING SPREAD OF INFECTION WITH VIRUSES OR BACTERIA THAT CAUSE PNEUMONIA IN PULMONARY BRONCHIAL EPITHELIAL CELLS OR ALVEOLAR EPITHELIAL CELLS, AND NASAL SPRAY | NEXT21 KABUSHIKI KAISHA (JP) | 2023-02-09 | — | — | US | disclosed |
| US-11464788-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2022-10-11 | — | — | US | disclosed |
| EP-4043007-A1 | PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID | Toray Industries, Inc. (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502142-A | Pharmaceutical compositions comprising temperature-responsive ionic liquids | 东丽株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20220142915-A1 | Dental Local Anesthetic Solution | SHOWAKAI MEDICAL CO. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3995132-A1 | DENTAL LOCAL ANESTHETIC SOLUTION | Showakai Medical Co. (JP) | 2022-05-11 | — | — | EP | disclosed |
| CN-114174318-A | Carrier for kidney-targeted drug delivery having excellent biodegradability | 学校法人京都药科大学 | 2022-03-11 | — | — | CN | disclosed |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS (US) | 2022-03-10 | — | — | US | disclosed |
| CN-107530275-B | Adhesive polymer matrix for iontophoresis and device for iontophoresis comprising the same | 菲力格林公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11007138-B2 | Adhesive polymer matrix for iontophoresis and device for iontophoresis including said matrix | FEELIGREEN (FR) | 2021-05-18 | — | — | US | disclosed |
| CN-108430477-B | Pharmaceutical composition comprising glucocorticoid compound for treating lung cancer | 亚洲大学校产学协力团 | 2021-05-14 | — | — | CN | disclosed |
| WO-2021070893-A1 | PHARMACEUTICAL COMPOSITION INCLUDING TEMPERATURE-RESPONSIVE IONIC LIQUID | 東レ株式会社 | 2021-04-15 | — | — | WO | disclosed |
| US-20210038616-A1 | SOLID OILY EXTERNAL COMPOSITION | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| WO-2021002481-A1 | RENAL TARGETING-TYPE DRUG DELIVERY CARRIER HAVING EXCELLENT BIODEGRABILITY | 学校法人京都薬科大学 | 2021-01-07 | — | — | WO | disclosed |
| EP-3038660-B1 | COMPOUND OF GLYCOSAMINOGLYCAN AND ITS PREPARATION METHOD AS WELL AS APPLICATION | AIHOL CORP (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-111278894-A | Kidney targeting drug delivery carrier | 学校法人京都药科大学 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019189756-A1 | SOLID OILY TOPICAL COMPOSITION | ロート製薬株式会社 | 2019-10-03 | — | — | WO | disclosed |
| CN-109111446-A | A kind of heteroaryl compound with pharmaceutical activity | 上海度德医药科技有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20180256599-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2018-09-13 | — | — | US | disclosed |
| US-20180243210-A1 | METHOD FOR TREATING INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2018-08-30 | — | — | US | disclosed |
| US-9980902-B2 | Method for treating intestinal fibrosis | SIGMOID PHARMA LIMITED (IE) | 2018-05-29 | — | — | US | disclosed |
| EP-3322482-A1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | Parikh, Nilesh (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180092834-A1 | ADHESIVE POLYMER MATRIX FOR IONTOPHORESIS AND DEVICE FOR IONTOPHORESIS INCLUDING SAID MATRIX | FEELIGREEN (FR) | 2018-04-05 | — | — | US | disclosed |
| CN-107530275-A | For the adhesive polymer matrix of iontophoresis and the device for iontophoresis including the matrix | 菲力格林公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170080049-A1 | MEDICINE AGAINST GROWTH FAILURE INDUCED BY ADMINISTRATION OF STEROID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3135296-A1 | MEDICINE AGAINST GROWTH IMPAIRMENT INDUCED BY ADMINISTRATION OF STEROID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-2460540-B1 | KIDNEY-TARGETING DRUG DELIVERY AGENT COMPRISING RECOMBINANT GELATIN | FUJIFILM CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| WO-2017011071-A1 | TOPICAL CIPROFLOXACIN COMPOSITIONS | PARIKH NILESH (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| EP-1985309-B1 | NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG | LTT BIO PHARMA CO LTD (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160213611-A1 | METHOD FOR TREATING INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2016-07-28 | — | — | US | disclosed |
| US-9393243-B1 | Topical Ciprofloxacin compositions | XAVION LIFESCIENCES, LLC | 2016-07-19 | — | — | US | disclosed |
| US-9320746-B2 | Method for treating intestinal fibrosis | SIGMOID PHARMA LIMITED (IE) | 2016-04-26 | — | — | US | disclosed |
| EP-2958579-A1 | ORAL STEROID FORMULATIONS FOR USE IN THE TREATMENT OF INTESTINAL FIBROSIS | Sigmoid Pharma Limited (IE) | 2015-12-30 | — | — | EP | disclosed |
| CN-102977175-B | Aminoglucose sugar derivatives is as the purposes of small-molecule drug kidney targeting modification group | SICHUAN UNIVERSITY (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-105073127-A | Oral steroid formulations for use in the treatment of intestinal fibrosis | SIGMOID PHARMA LTD | 2015-11-18 | — | — | CN | disclosed |
| US-9051335-B2 | Antipruritic agent for pruritus caused by multiple sclerosis | TORAY INDUSTRIES, INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-8916206-B2 | Nanoparticles containing water-soluble non-peptide low-molecular weight drug | LTT BIO-PHARMA CO., LTD. (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8906111-B2 | Artificial bone material having controlled calcium ion elution | THE UNIVERSITY OF TOKYO (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS | 2014-10-16 | — | — | US | disclosed |
| WO-2014128233-A1 | ORAL STEROID FORMULATIONS FOR USE IN THE TREATMENT OF INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2014-08-28 | — | — | WO | disclosed |
| US-20140234418-A1 | METHOD FOR TREATING INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2014-08-21 | — | — | US | disclosed |
| US-8796248-B2 | Oligomer-corticosteroid conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8545873-B2 | Percutaneous absorption type plaster | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-1870413-B1 | ANTIPRURITIC AGENT FOR PRURITUS CAUSED BY MULTIPLE SCLEROSIS | TORAY INDUSTRIES (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2582357-A1 | TRANSDERMAL ABSORPTION PROMOTER, AND EXTERNAL SKIN FORMULATION THEREOF | Takasago International Corporation (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-20130084257-A1 | TRANSDERMAL ABSORPTION PROMOTER, AND EXTERNAL SKIN FORMULATION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-04 | — | — | US | disclosed |
| CN-102977175-A | Application of glucosamine derivatives as small molecule drug kidney-targeting modifying groups | UNIV SICHUAN | 2013-03-20 | — | — | CN | disclosed |
| US-8275454-B2 | Iontophoresis device activated in use | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120196807-A1 | KIDNEY-TARGETING DRUG DELIVERY AGENT COMPRISING RECOMBINANT GELATIN | FUJIFILM CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120171278-A1 | PERCUTANEOUS ABSORPTION TYPE PLASTER | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2460540-A1 | KIDNEY-TARGETING DRUG DELIVERY AGENT COMPRISING GENETICALLY MODIFIED GELATIN | FUJIFILM Corporation (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120095386-A9 | COMPOSITION AND DEVICE STRUCTURE FOR IONTOPHORESIS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8158145-B2 | Multilayer transdermal laminate patch with backing, adhesive | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8155738-B2 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| WO-2011158964-A1 | TRANSDERMAL ABSORPTION PROMOTER, AND EXTERNAL SKIN FORMULATION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-12-22 | — | — | WO | disclosed |
| US-20110183000-A1 | ARTIFICIAL BONE MATERIAL HAVING CONTROLLED CALCIUM ION ELUTION | NEXT21 K.K. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110152743-A1 | IONTOPHORESIS DEVICE ACTIVATED IN USE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2308519-A1 | ARTIFICIAL BONE MATERIAL HAVING CONTROLLED CALCIUM ION ELUTION | NEXT21 K.K. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110021972-A1 | Composition and Device Structure For Iontophoresis | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-1151749-B1 | SHEET-FORM ADHESIVE PREPARATION | HISAMITSU PHARMACEUTICAL CO (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| CN-1731981-B | Liposome of glucocorticoids | NOVOSOM AG | 2010-06-16 | — | — | CN | disclosed |
| US-20100129456-A1 | SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP | LTT BIO-PHARMA CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2156848-A1 | LOW-MOLECULE DRUG-CONTAINING NANOPARTICLE HAVING SUSTAINED RELEASE NEGATIVELY CHARGED GROUP | LTT Bio-Pharma Co., Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| US-20090317479-A1 | NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG | LTT BIO-PHARMA CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7625620-B2 | Sheet-type patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090280177-A1 | Pharmaceutical preparation for treating fibromyalgia | AXIS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-100546656-C | A kind of kidney-targeted medicine vector reaches prodrug, method for making and the application with its formation | UNIV SICHUAN (CN) | 2009-10-07 | — | — | CN | disclosed |
| US-20090232855-A1 | Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same | KWON SUN SANG | 2009-09-17 | — | — | US | disclosed |
| CN-100518832-C | Kidney target precursor medicine, said prepn., its preparing method and application | UNIV SICHUAN (CN) | 2009-07-29 | — | — | CN | disclosed |
| EP-2077114-A1 | PHARMACEUTICAL PREPARATION FOR TREATING FIBROMYALGIA | St. Marianna University School of Medicine (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20090171376-A1 | Mesh Anchoring System | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-07-02 | — | — | US | disclosed |
| US-20090170888-A1 | Antipruritic Agent for Pruritus Caused by Multiple Sclerosis | TORAY INDUSTRIES, INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20080287467-A1 | Therapeutic Agent for Respiratory Diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1985309-A1 | NANOPARTICLE CONTAINING WATER-SOLUBLE NON-PEPTIDIC LOW MOLECULAR WEIGHT SUBSTANCE | LTT Bio-Pharma Co., Ltd. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| CN-101247786-A | Oral suspension of prednisolone acetate | TARO PHARMACEUTICALS NORTH AME (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| EP-1206937-B1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR THE TREATMENT OF ATOPIC DERMATITIS | SHOEI CO LTD (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-1870413-A1 | ANTIPRURITIC AGENT FOR PRURITUS CAUSED BY MULTIPLE SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007056384-A2 | MESH ANCHORING SYSTEM | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070077286-A1 | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | LTT BIO-PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1754712-A2 | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070020325-A1 | Hydrogel composition | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7160551-B2 | Nonaqueous biocompatible solvent, a biodegradable hydrophobic polymer, and an amphiphilic block copolymer such as ethylene oxide-propylene oxide triblock copolymer; use as an injectable implant; no initial \"burst\ | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| CN-1879889-A | Kidney-targeted medicine vector and the formed prodrug, preparation method and uses | UNIV SICHUAN (CN) | 2006-12-20 | — | — | CN | disclosed |
| CN-1861193-A | Kidney target precursor medicine, said prepn., its preparing method and application | UNIV SICHUAN (CN) | 2006-11-15 | — | — | CN | disclosed |
| US-20060233883-A1 | Intravenous nanoparticles for targeting drug delivery and sustained drug release | LTT BIO-PHARMA CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1249232-B1 | Controlled release nanoparticles for percutaneous use and composition containing the same | PACIFIC CORP (KR) | 2006-10-11 | — | — | EP | disclosed |
| EP-1698329-A1 | DRUG-CONTAINING NANOPARTICLE, PROCESS FOR PRODUCING THE SAME AND PARENTERALLY ADMINISTERED PREPARATION FROM THE NANOPARTICLE | LTT Bio-Pharma Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-07-27 | — | — | US | disclosed |
| US-20060147511-A1 | Liposomal glucocorticoids | PANZNER STEFFEN | 2006-07-06 | — | — | US | disclosed |
| US-20060140991-A1 | Pharmaceutical preparations having an improved solubility | AJINOMOTO CO. INC (JP) | 2006-06-29 | — | — | US | disclosed |
| US-7064242-B2 | Patch | HISAMITSU PHARMACEUTICALS CO., INC. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1661556-A1 | MEDICINAL PREPARATION HAVING IMPROVED DISSOLUTION PROPERTIES | Ajinomoto Co., Inc. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-7041818-B2 | DDS compound and method for measurement thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20060030801-A1 | Patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2006-02-09 | — | — | US | disclosed |
| CN-1731981-A | Liposomal glucocorticoids | NOVOSOM AG (DE) | 2006-02-08 | — | — | CN | disclosed |
| EP-1619210-A1 | DDS compounds and method for assaying the same | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050271725-A1 | Adhesive gel composition for iontophoresis preparation and process for producing the same | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1594482-A1 | INTRAVENOUS NANOPARTICLES FOR TARGETING DRUG DELIVERY AND SUSTAINED DRUG RELEASE | LTT Bio-Pharma Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| US-6936268-B1 | Sheet-form adhesive preparation | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20050181163-A1 | Sheet-type patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1547579-A1 | ADHESIVE GEL COMPOSITION FOR IONTOPHORESIS PREPARATION AND PROCESS FOR PRODUCING THE SAME | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20050129748-A1 | Percutaneous absorption type plaster | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6838450-B2 | Residue of a drug compound such as antineoplastic agents and a carboxy(C1-4) alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2005-01-04 | — | — | US | disclosed |
| US-6835807-B1 | Drug complex and drug delivery system | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| EP-1477164-A1 | PERCUTANEOUS ABSORPTION TYPE PLASTER | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6811996-B1 | COMPRISING A CARBOXY(C1-4) ALKYLDEXTRAN POLYALCOHOL MODIFIED WITH A SACCHARIDE AND A DRUG (ANTINEOPLASTIC) RESIDUE; TREATING DRUG DELIVERY SYSTEM (DDS) WITH A PEPTIDASE AND MEASURING RESULTING HYDROLYSATE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| WO-2004084871-A1 | INTRAVENOUS NANOPARTICLES FOR TARGENTING DRUG DELIVERY AND SUSTAINED DRUG RELEASE | LTT BIO-PHARMA CO., LTD. (JP) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192644-A1 | DDS compound and method for measurement thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-30 | — | — | US | disclosed |
| EP-0955064-B1 | PROCESS FOR PRODUCING DRUG COMPLEXES | DAIICHI SEIYAKU CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-0916348-B1 | alkyldextran-polyalcohol drug complexes | DAIICHI SEIYAKU CO (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040156886-A1 | Sheet-like patch agent | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-08-12 | — | — | US | disclosed |
| US-6743432-B1 | MEMBRANE HAVING LOW ADSORPTIVITY FOR PROTEIN; HOMO- OR CO-POLYMER OF FLUORINE-CONTAINING MONOMER INCLUDING HYDROPHILIC GROUP, HYDROPHILIZED POLYSULFONE INCORPORATING WETTING AGENT, HYDROPHILIZED CELLULOSE DERIVATIVE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20040071765-A1 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| WO-2004004688-A1 | INJECTABLE SYSTEM FOR CONTROLLED DRUG DELIVERY | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20040009226-A1 | Injectable system for controlled drug delivery | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2004-01-15 | — | — | US | disclosed |
| EP-1374861-A1 | External preparations for treating dermatoses | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0747092-B1 | Matrix for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-0766960-B1 | EXTERNAL PREPARATIONS FOR TREATING DERMATOSES | SEIKISUI CHEMICAL CO LTD (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-20030171262-A1 | Residue of a drug compound such as antineoplastic agents and a carboxy(C1-4) alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-20030171343-A1 | Percutaneous absorption type steroid preparation for external use | NICHIBAN CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-0748636-B1 | Interface for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1334114-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6597947-B1 | Iontophoresis device | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | SHOEI CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1300152-A1 | PERCUTANEOUS ABSORPTION TYPE STEROID PREPARATION FOR EXTERNAL USE | Nichiban Company Limited (JP) | 2003-04-09 | — | — | EP | disclosed |
| EP-1022020-B1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1249232-A1 | Controlled release nanoparticles for percutaneous use and composition containing the same | PACIFIC CORPORATION (KR) | 2002-10-16 | — | — | EP | disclosed |
| US-6436912-B1 | DRUG COMPLEX COMPRISING CARBOXY(C.SUB.1-4)ALKYLDEXTRAN POLYALCOHOL AND RESIDUE OF DRUG COMPOUND BOUND TO EACH OTHER WITH SPACER COMPRISING AMINO ACID OR SPACER COMPRISING PEPTIDE-BONDED 2 TO 8 AMINO ACIDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-0698393-B1 | 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1177813-A1 | IONTOPHORESIS DEVICE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6328979-B1 | Sustained release medicinal compositions | YAMANOUCHI PHARMACEUTICALS, CO. LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1155702-A1 | DDS COMPOUNDS AND METHOD FOR ASSAYING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-1151749-A1 | SHEET-FORM ADHESIVE PREPARATION | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-6306898-B1 | MIXTURE OF VITAMIN E AND SQUALANE FOR SKIN DISORDERS | SEKISUI KAISHA KOGYO KABUSHIKI KAISHA (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0732122-B1 | Stabilized interface for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-6291671-B1 | REACTING ORGANIC AMINE SALT OF POLYSACCHARIDE DERIVATIVE HAVING CARBOXYL GROUPS WITH DRUG COMPOUND OR SPACER BOUND TO COMPOUND IN NONAQUEOUS SYSTEM; BY-RODUCT INHIBITION; DRUG DELIVERY CARRIERS FOR ANTINEOPLASTIC/ANTIINFLAMMATORY AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6248779-B1 | SYNERGISTIC MIXTURE OF VITAMIN E AND SQUALANE | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6248349-B1 | LIQUID HUMECTANT | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-1080732-A1 | DRUG COMPOSITES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080731-A2 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-0709085-B1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | EP | disclosed |
| EP-0800385-B1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-6159502-A | Oral delivery systems for microparticles | BIOTECH AUSTRALIA PTY LTD (AU) | 2000-12-12 | — | — | US | disclosed |
| EP-1043031-A1 | SUSTAINED RELEASE MEDICINAL COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6117455-A | A SUSTAINED-RELEASE MICROCAPSULE THAT HAS A HIGH ENTRAPMENT OF A WATER-SOLUBLE DRUG AND CAUSES A SMALL INITIAL RELEASE, MICROCAPSULE COMPRISING AN AMORPHOUS WATER-SOLUBLE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND A POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-12 | — | — | US | disclosed |
| US-6113941-A | POLYMER WITH IMIDAZOLE, BENZIMIDAZOLE, TRIAZOLE AND ALANYL GLYCINE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-1022020-A2 | Sustained-release preparation | Takeda Chemical Industries, Ltd. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0997144-A1 | PLASTICIZER AND PATCH CONTAINING THE PLASTICIZER | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0979085-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5993848-A | Dissolution liquid for drug in iontophoresis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0955064-A1 | PROCESS FOR PRODUCING DRUG COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-11-10 | — | — | EP | disclosed |
| US-5908400-A | DRUG DELIVERY | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0916348-A1 | DRUG COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5891920-A | Medicinal adjuvants consisting of N-subsitituted-o-toluidine derivatives, and percutaneously absorbable preparations comprising the adjuvants | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5854384-A | Process for preparing poly-α-amino acid particles | SR CORPORATION (JP) | 1998-12-29 | — | — | US | disclosed |
| US-5837713-A | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-11-17 | — | — | US | disclosed |
| US-5837281-A | Stabilized interface for iontophoresis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-17 | — | — | US | disclosed |
| WO-1998037896-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5725874-A | MENTHOXYPROPANEDIOL | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-03-10 | — | — | US | disclosed |
| EP-0582459-B1 | Production of microcapsules of water-soluble drugs | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0813887-A2 | A device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1997-12-29 | — | — | EP | disclosed |
| EP-0800385-A1 | ORAL SUSTAINED-RELEASE PREPARATION | Takeda Chemical Industries, Ltd. (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0531497-B1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-08-13 | — | — | EP | disclosed |
| US-5631021-A | TIME RELEASE MIXTURES FROM OIL IN WATER EMULSIONS AND DRUGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| US-5631020-A | LUTEINIZING HORMONE-RELEASING HORMONE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| EP-0766960-A1 | EXTERNAL PREPARATIONS FOR TREATING DERMATOSES | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-04-09 | — | — | EP | disclosed |
| US-5611971-A | Production of microcapsules of water-soluble drugs | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0748636-A2 | Interface for iontophoresis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0747092-A2 | Dissolution liquid for drug in iontophoresis | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
| EP-0732122-A1 | Stabilized interface for iontophoresis | Takeda Chemical Industries, Ltd. (JP) | 1996-09-18 | — | — | EP | disclosed |
| EP-0709085-A1 | Sustained-release preparation | Takeda Chemical Industries, Ltd. (JP) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996010397-A1 | ORAL SUSTAINED-RELEASE PREPARATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | disclosed |
| EP-0698393-A1 | SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5476663-A | Particles containing water soluble drug dispersed in spherical microcapsule matrix composed of copolymer of lactic acid and glycolic acid, excipient; for injection | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | disclosed |
| EP-0481732-B1 | Prolonged release preparation and polymers thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | disclosed |
| US-5330767-A | Sustained release microcapsule | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-19 | — | — | US | disclosed |
| US-5304377-A | Blend of polylactic acid and glycolic acid copolymer | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| EP-0582459-A2 | Production of microcapsules of water-soluble drugs | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0531497-A4 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | — | 1993-12-22 | — | — | EP | disclosed |
| EP-0531497-A1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES. | BIOTECH AUSTRALIA PTY LTD (AU) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992017167-A1 | ORAL DELIVERY SYSTEMS FOR MICROPARTICLES | BIOTECH AUSTRALIA PTY. LTD. (AU) | 1992-10-15 | — | — | WO | disclosed |
| EP-0481732-A1 | Prolonged release preparation and polymers thereof | Takeda Chemical Industries, Ltd. (JP) | 1992-04-22 | — | — | EP | disclosed |
| US-5061492-A | biodegeadeable polymer matrix is copolymer of gylcolic acid a nd lactic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0190833-B1 | METHOD FOR PRODUCING MICROCAPSULE | Takeda Chemical Industries, Ltd. (JP) | 1991-03-27 | — | — | EP | disclosed |
| US-4954298-A | Method for producing microcapsule | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4917893-A | Prolonged release microcapsules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0145240-B1 | METHOD FOR PRODUCING MICROCAPSULE | Takeda Chemical Industries, Ltd. (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | disclosed |
| US-4652441-A | WATER SOLUBLE DRUGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0190833-A2 | Method for producing microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
| EP-0145240-A2 | Method for producing Microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0145240-A2 | Method for producing Microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021972-A1 | Composition and Device Structure For Iontophoresis | ASIC1, AQP1, PIEZO1 | HIF1A 1691/4885HSD17B10 3586/4885NR3C1 3377/4885 |
| US-20040192644-A1 | DDS compound and method for measurement thereof | SI, DPP8, CES1 | HIF1A 3667/4885HSD17B10 185/4885NR3C1 2240/4885 |
| US-20240058452-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TEMPERATURE-RESPONSIVE IONIC LIQUID | SULT1A1, CYP2C19, SULT2A1 | HIF1A 3520/4885HSD17B10 463/4885NR3C1 1864/4885 |
| US-11464788-B2 | Oligomer-corticosteroid conjugates | SERPINA6, NR3C2, NR3C1 | HIF1A 4810/4885HSD17B10 891/4885NR3C1 3/4885 |
| US-20250064749-A1 | CELL-ADHESIVE COMPOSITION AND POLYMER-COATED MICROPARTICLES | EPCAM, ICAM1, H1-10 | HIF1A 799/4885HSD17B10 1646/4885NR3C1 1955/4885 |
| US-20060166862-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | HIF1A 3432/4885HSD17B10 2144/4885NR3C1 2616/4885 |
| US-20230099756-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL6 | HIF1A 4135/4885HSD17B10 2069/4885NR3C1 624/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | HIF1A 3432/4885HSD17B10 2144/4885NR3C1 2616/4885 |
| US-20220072010-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C2, NR3C1 | HIF1A 4810/4885HSD17B10 891/4885NR3C1 3/4885 |
| US-20040071765-A1 | Composition and device structure for iontophoresis | ASIC1, AQP1, PIEZO1 | HIF1A 1849/4885HSD17B10 3508/4885NR3C1 3719/4885 |
| US-20240336697-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL6 | HIF1A 4135/4885HSD17B10 2069/4885NR3C1 624/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | HIF1A 4459/4885HSD17B10 237/4885NR3C1 1/4885 |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | IL4I1, NSD1, CUTA | HIF1A 1028/4885HSD17B10 1707/4885NR3C1 46/4885 |
| US-20120095386-A9 | COMPOSITION AND DEVICE STRUCTURE FOR IONTOPHORESIS | ASIC1, AQP1, PIEZO1 | HIF1A 1691/4885HSD17B10 3586/4885NR3C1 3377/4885 |
| US-20090170888-A1 | Antipruritic Agent for Pruritus Caused by Multiple Sclerosis | OPRM1, OPRK1, OPRL1 | HIF1A 1776/4885HSD17B10 3909/4885NR3C1 483/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | HIF1A 4786/4885HSD17B10 912/4885NR3C1 3/4885 |
| US-20140309398-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C1, NR3C2 | HIF1A 4721/4885HSD17B10 711/4885NR3C1 2/4885 |
| US-20030171262-A1 | Residue of a drug compound such as antineoplastic agents and a carboxy(C1-4) alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a | PCNA, DCLRE1A, TPD52L2 | HIF1A 1832/4885HSD17B10 1816/4885NR3C1 1662/4885 |
| US-20060140991-A1 | Pharmaceutical preparations having an improved solubility | SI, LSS, PDE8B | HIF1A 2142/4885HSD17B10 2433/4885NR3C1 4780/4885 |
| US-20180256599-A1 | OLIGOMER-CORTICOSTEROID CONJUGATES | SERPINA6, NR3C2, NR3C1 | HIF1A 4810/4885HSD17B10 891/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.